Evonik's €10.3 Billion Standoff: BASF's Overture, a Rejected Bid, and a Restructuring Race Against the Clock

BASF reportedly keeps working on a deal after Evonik rejected a €22.15-per-share offer, while Evonik's own savings won't fully land until 2029.

Evonik finds itself squeezed between two clocks that tick at very different speeds. One belongs to BASF, which is reportedly still circling the Essen-based specialty chemicals maker despite being shown the door once already. The other belongs to Evonik's own turnaround, a multi-year effort whose biggest savings won't land until the end of the decade. How those two timelines intersect will likely decide where the share goes from here.

A Bid Deemed Too Low, and a Suitor That Hasn't Walked Away

The takeover storyline took shape in stages. Evonik turned down an initial offer, judging it insufficient to justify formal negotiations, according to Reuters. The Financial Times later reported that BASF had put roughly €22.15 per share on the table — a package worth €10.3 billion in total. Neither company has commented officially on the specific price demands.

Then, on Tuesday, Handelsblatt reported that BASF is continuing to work on a deal notwithstanding the rebuff. Whether a fresh offer materializes, and when, remains an open question. What the rejection does make clear is the level of expectation inside Evonik: management wants a richer valuation for the specialty chemicals business before it sits down for deeper talks. In the meantime, the prospect of another attempt keeps traders engaged.

The Homegrown Fix: 3,200 Jobs and Two Divestments

Parallel to the courtship, Evonik is pressing ahead with its own agenda. On 22 September the company announced it would continue its "Evonik Tailor Made" program, a savings and restructuring push that will eliminate 3,200 positions worldwide — about 2,150 of them in Germany. The goal is a permanently leaner cost base, and the strategic sharpening serves a dual purpose: it strengthens the operating foundation while widening Evonik's room to maneuver in any future negotiation.

Management is also betting on a tighter focus, steering sites and investments according to clearly defined role profiles to lift efficiency. Divestments form a key plank of that plan. The sales of the peripheral businesses Oxeno and Syneqt are being driven forward on schedule, according to the company. If those disposals go smoothly, Evonik gains extra financial headroom that could be channeled into higher-margin core operations.

Why the Calendar Is the Real Constraint

Patience is not optional here. Because compulsory redundancies have been ruled out, the job reductions require extensive consultation and must be carried out in a socially acceptable way — a process that naturally caps the pace of structural cost savings. The second phase of Evonik Tailor Made isn't slated to begin until 2027 and would run through 2029, meaning meaningful relief on the cost side is still some way off.

That long runway cuts both ways. The bull case rests on the potential of the internal overhaul: if the targeted efficiency gains materialize and the portfolio is streamlined, the operating base emerges sustainably stronger. The stock's recent behavior offers some encouragement on that front — on Thursday it touched a 52-week high of €20.64. For the optimistic camp, that shows the market is rewarding the realignment, and a successful restructuring could lift the shares further even without an external offer.

Two Analysts, Two Very Different Price Tags

Not everyone is convinced. On Monday, the DZ Bank responded to the takeover rumors, with analyst Peter Spengler raising his fair value estimate to €22 from €21 while keeping a "Buy" rating. JPMorgan struck a far more cautious tone the same day, reaffirming a "Sell" rating with a price target of €14.00. The gulf between those two numbers captures the valuation risk baked into the current situation: takeover speculation is propping up the stock, while skeptics point to substantial hurdles standing in the way of any transaction.

The shares closed at €20.60 on Wednesday, hovering just below that 52-week peak of €20.64. Year to date, the stock has climbed 54%, leaving investors to weigh how much substance the standalone realignment actually carries.

What Could Break the Stalemate — in Either Direction

Execution risk looms large over the bullish narrative. The program stretches across a long horizon, and with phase two not starting until 2027, the wait for cost relief is considerable. If negotiations drag on, the transformation could lose momentum, and delays on the Oxeno and Syneqt sales are hardly out of the question in the current market environment. Should takeover enthusiasm fade while the restructuring pace disappoints, the stock faces a noticeable setback.

For now, the picture narrows to a straightforward test. As long as the divestment processes for Oxeno and Syneqt stay on plan, the bull case retains its validity, and investors are likely to grant management the necessary runway. If the schedule slips or the separations stall, market skepticism should build — and without visible progress on focusing the portfolio, confidence in the long-term targets through 2029 could erode, potentially prompting a swift downward repricing.

The next concrete catalysts are official completion notices on the Oxeno and Syneqt disposals, alongside any detail on how the Tailor Made phase will be structured. A further window into the company's operating health arrives on 3 November, when Evonik reports third-quarter 2026 figures. Between long-term transformation potential and tangible execution risk, shareholders have a clear choice to make.